Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.
Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.
Exp Eye Res. 2014 Apr;121:94-101. doi: 10.1016/j.exer.2014.01.011. Epub 2014 Jan 31.
Although sphingosine 1-phosphate (S1P), a bioactive lipid derived from activated platelets, has a variety of physiologic effects on vessels, no reports have described the effect of S1P on the retinal circulation. We examined the effect and underlying mechanism of the vasomotor action of S1P on porcine retinal arterioles. The porcine retinal arterioles were isolated, cannulated, and pressurized without flow for in vitro study. S1P-induced diameter changes were recorded using videomicroscopic techniques. S1P elicited concentration-dependent (1 nM-10 μM) vasoconstriction of the retinal arterioles that was abolished by the S1P receptor 2 (S1PR2) antagonist JTE-013. S1P-induced vasoconstriction was abolished by the Rho kinase (ROCK) inhibitor H-1152 and was inhibited partly by the protein kinase C (PKC) inhibitor Gö-6983. The inhibition of phospholipase C by U73122 and L-type voltage-operated calcium channels (L-VOCCs) by nifedipine inhibited S1P-induced vasoconstriction; a combination of both inhibitors abolished S1P-induced vasoconstriction. Furthermore, inhibition of myosin light chain kinase (MLCK) by ML-9 significantly blocked S1P-induced vasoconstriction; further coadministration of ML-9 with H-1152 or Gö-6983 abolished S1P-induced vasoconstriction. The current data suggest that S1P elicits vasoconstriction of the retinal arterioles via S1PR2 in vascular smooth muscle cells and this vasoconstriction may be mediated by the Ca2+ -sensitive pathway via activation of PKC leading to activation of ROCK and the Ca2+ -dependent pathway via activation of L-VOCCs resulting in activation of MLCK.
尽管来源于激活血小板的鞘氨醇 1-磷酸(S1P)对血管具有多种生理作用,但尚无关于 S1P 对视网膜循环影响的报道。我们研究了 S1P 对猪视网膜小动脉舒缩作用的影响及其潜在机制。将猪视网膜小动脉分离、插管并在无流量的情况下加压进行体外研究。使用视频显微镜技术记录 S1P 诱导的直径变化。S1P 诱导视网膜小动脉产生浓度依赖性(1 nM-10 μM)收缩,该收缩可被 S1P 受体 2(S1PR2)拮抗剂 JTE-013 消除。S1P 诱导的收缩被 Rho 激酶(ROCK)抑制剂 H-1152 部分消除,并被蛋白激酶 C(PKC)抑制剂 Gö-6983 部分抑制。U73122 抑制磷脂酶 C 和硝苯地平抑制 L-型电压门控钙通道(L-VOCCs),可抑制 S1P 诱导的收缩;联合使用两种抑制剂可消除 S1P 诱导的收缩。此外,肌球蛋白轻链激酶(MLCK)抑制剂 ML-9 显著阻断 S1P 诱导的收缩;进一步与 H-1152 或 Gö-6983 联合给药可消除 S1P 诱导的收缩。目前的数据表明,S1P 通过血管平滑肌细胞中的 S1PR2 引起视网膜小动脉收缩,这种收缩可能通过激活 PKC 导致 ROCK 激活的 Ca2+敏感途径介导,以及通过激活 L-VOCCs 导致 MLCK 激活的 Ca2+依赖性途径介导。